中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

56 records (took 0.016 seconds)

    CCAT-1 SILENCING NUCLEIC ACID AGENTS FOR TREATING CANCER
    1.
    发明申请
    CCAT-1 SILENCING NUCLEIC ACID AGENTS FOR TREATING CANCER 审中-公开
    CCAT-1用于治疗癌症的沉默性核酸试剂

    公开(公告)号：WO2012131673A3

    公开(公告)日：2012-11-22

    申请号：PCT/IL2012000136

    申请日：2012-03-29

    Applicant: HADASIT MED RES SERVICE ,  MOR RESEARCH APPLIC LTD ,  NISSAN AVIRAM ,  HALLE DAVID ,  OSMAY GURE ALI ,  TSIVIN VICTORIA ,  PAVLOV VERA

    Inventor： NISSAN AVIRAM ,  HALLE DAVID ,  OSMAY GURE ALI ,  TSIVIN VICTORIA ,  PAVLOV VERA

    IPC: C12N5/10

    CPC classification number: C12N15/113 ,  C12N2310/14 ,  C12N2310/531

    Abstract: The invention provides compositions and methods useful for inhibiting or preventing cancer, comprising nucleic acid agents capable of silencing or reducing the expression of the CCAT -1 gene for the treatment of cancer. The present invention discloses for the first time that small interfering RNA (siRNA) agents directed to CCAT-I can exert a beneficial effect in anti-cancer therapy. In particular, small interfering RNA (siRNA) and short hairpin RNA (shRNA) targeting CCAT-I inhibited cancer cell proliferation and reduced cancer cell migration. The terms siRNA and shRNA indicate double-stranded RNA capable of inducing RNA interference (RNAi) by cleavage of a target gene RNA transcript and are composed of a sense RNA strand having highly homologous sequence to a fragment of the target gene RNA and an antisense RNA strand having the complementary sequence to the target gene.

    Abstract translation: 本发明提供了可用于抑制或预防癌症的组合物和方法，其包含能够沉默或降低CCAT-1基因表达以治疗癌症的核酸试剂。 本发明首次公开了针对CCAT-1的小干扰RNA（siRNA）试剂可以在抗癌治疗中发挥有益作用。 特别地，针对CCAT-1的小干扰RNA（siRNA）和短发夹RNA（shRNA）抑制癌细胞增殖并减少癌细胞迁移。 术语siRNA和shRNA表示能够通过切割靶基因RNA转录物诱导RNA干扰（RNAi）的双链RNA，并且由与靶基因RNA的片段和反义RNA具有高同源序列的正义RNA链组成 链与靶基因具有互补序列。

    USE OF HGH FOR THE TREATMENT OF SMALL FOR GESTATIONAL AGE INFANTS UNDER TWO YEARS OF AGE
    2.
    发明申请
    USE OF HGH FOR THE TREATMENT OF SMALL FOR GESTATIONAL AGE INFANTS UNDER TWO YEARS OF AGE 审中-公开
    HGH用于治疗年龄两岁以下的妊娠年龄婴儿的小鼠

    公开(公告)号：WO2012104838A8

    公开(公告)日：2012-09-27

    申请号：PCT/IL2012000055

    申请日：2012-01-31

    Applicant: MOR RESEARCH APPLIC LTD ,  LARON ZVI

    Inventor： LARON ZVI

    IPC: A61K38/25 ,  A61K38/27 ,  A61K38/30 ,  A61P43/00

    CPC classification number: A61K38/27 ,  A61K38/25 ,  A61K38/30

    Abstract: The invention provides a method and a composition for the treatment of infants age less than 2.5 years old defined as small for gestational age (SGA), including the use of hGH or any compound that increases blood levels of hGH or of IGF-I. Early use of the composition prevents the irreversible neurological and psychological damage of the children.

    Abstract translation: 本发明提供了一种用于治疗年龄小于2.5岁的年龄小于胎龄（SGA）的婴儿的方法和组合物，包括使用hGH或任何增加hGH或IGF-I血液水平的化合物。 早期使用组合物可防止儿童不可逆转的神经和心理损伤。

    HALLUX ABDUCTO VALGUS ASSEMBLIES
    4.
    发明申请
    HALLUX ABDUCTO VALGUS ASSEMBLIES 审中-公开

    公开(公告)号：WO2010106507A3

    公开(公告)日：2010-11-18

    申请号：PCT/IB2010051155

    申请日：2010-03-17

    Applicant: MOR RESEARCH APPLIC LTD ,  ROBINSON DROR

    Inventor： ROBINSON DROR

    IPC: A61B17/17 ,  A61B17/68 ,  A61B17/80

    CPC classification number: A61B17/68 ,  A61B17/8085 ,  A61B17/842 ,  A61B17/864 ,  A61B2017/565

    Abstract: Disclosed is an assembly for in vivo alignment of two or more bones in a living body. The assembly comprises a cannulated sleeve (132) configured to secure in a bore (133) in a first bone, a mesh body (136) having a proximal arm configured to be engaged by the cannulated sleeve, and a distal arm configured to be secured to a portion of a second bone. The assembly further includes a fastener (138) configured to secure the distal arm to the portion of the second bone.

    Abstract translation: 公开了一种用于活体内两个或多个骨的体内对准的组件。 组件包括构造成固定在第一骨中的孔（133）中的套管套管（132），具有被套管套筒接合的近端臂的网状体（136）和被构造成被固定的远侧臂 到第二骨的一部分。 组件还包括紧固件（138），其被构造成将远端臂固定到第二骨的部分。

    ACCESS TO THE LEFT ATRIUM AND REDUCTION OF MITRAL VALVE LEAFLET MOBILITY
    6.
    发明申请
    ACCESS TO THE LEFT ATRIUM AND REDUCTION OF MITRAL VALVE LEAFLET MOBILITY 审中-公开
    获得左心室和减少麻醉机叶片移动性

    公开(公告)号：WO2009072114A3

    公开(公告)日：2010-03-11

    申请号：PCT/IL2008001565

    申请日：2008-12-02

    Applicant: MOR RESEARCH APPLIC LTD ,  ORLOV BORIS

    Inventor： ORLOV BORIS

    IPC: A61F2/24

    CPC classification number: A61F2/2466 ,  A61B17/3421 ,  A61B17/3478 ,  A61B2017/00243 ,  A61B2017/00247 ,  A61B2017/00783 ,  A61B2017/22069 ,  A61B2017/22098 ,  A61B2017/308 ,  A61F2/2454 ,  A61F2/246 ,  A61F2/2463

    Abstract: Disclosed are a method for engaging cardiac valve leaflets, including a) directing a distal end of an elongated catheter body of a leaflet-engaging device into a coronary sinus of a heart, b) passing a first leaflet-engaging component located proximate to the distal end of the elongated catheter body of the leaflet-engaging device through cardiac tissue separating the coronary sinus and a left atrium of the heart to enter a left atrium of the heart, and c) engaging a first cardiac valve leaflet with the first leaflet-engaging component, thereby engaging at least one cardiac valve leaflet. Related apparatus and methods are also described.

    Abstract translation: 公开了一种用于接合心脏瓣膜小叶的方法，包括a）将小叶接合装置的细长导管体的远端引导到心脏的冠状窦中，b）使位于远端的第一小叶接合组件 通过分离冠状窦和心脏的左心房的心脏组织进入小叶接合装置的细长导管体的端部，以进入心脏的左心房，以及c）使第一心脏瓣膜小叶与第一传单接合 从而接合至少一个心脏瓣膜小叶。 还描述了相关装置和方法。

    METHOD AND KIT FOR DIAGNOSING AND PREDICTING HEPATITIS C VIRUS-RELATED NEOPLASTIC TRANSFORMATION
    10.
    发明申请
    METHOD AND KIT FOR DIAGNOSING AND PREDICTING HEPATITIS C VIRUS-RELATED NEOPLASTIC TRANSFORMATION 审中-公开
    用于诊断和预测HEPATITIS C病毒相关性神经变性的方法和工具

    公开(公告)号：WO2006085328A3

    公开(公告)日：2007-11-08

    申请号：PCT/IL2006000185

    申请日：2006-02-13

    Applicant: MOR RESEARCH APPLIC LTD ,  KLEIN AMI

    Inventor： KLEIN AMI

    IPC: C12Q1/70 ,  C07H21/04

    CPC classification number: C12Q1/706

    Abstract: The present invention relates to a method for predicting and/or diagnosing neoplastic transformation in a patient infected with HCV, wherein said method comprises the determination of the presence or absence of integration of HCV into the genome of host cells taken from said patient, and wherein the presence of HCV integration is used to identify the patient as being at high risk for developing or already having developed and HCV-related neoplastic condition.

    Abstract translation: 本发明涉及用于预测和/或诊断HCV感染患者的肿瘤转化的方法，其中所述方法包括确定HCV与从所述患者取得的宿主细胞的基因组中的整合是否存在，其中 使用HCV整合的存在来鉴定患者处于发展或已经发展和HCV相关肿瘤病症的高风险。

Patent Agency Ranking